May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Functional and Morphological Results After Bevacizumab (Avastin®) Treatment of Idiopathic Juxtafoveal Retinal Telangietasis
Author Affiliations & Notes
  • M. A. Gamulescu
    Ophthalmology, University of Regensburg, Regensburg, Germany
  • A. F. Walter
    Ophthalmology, University of Regensburg, Regensburg, Germany
  • H. Sachs
    Ophthalmology, University of Regensburg, Regensburg, Germany
  • H. Helbig
    Ophthalmology, University of Regensburg, Regensburg, Germany
  • Footnotes
    Commercial Relationships M.A. Gamulescu, None; A.F. Walter, None; H. Sachs, None; H. Helbig, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4160. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. A. Gamulescu, A. F. Walter, H. Sachs, H. Helbig; Functional and Morphological Results After Bevacizumab (Avastin®) Treatment of Idiopathic Juxtafoveal Retinal Telangietasis. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4160.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Idiopathic juxtafoveal retinal telangiectasis (JRT) are a rare cause of visual impairement in the middle-aged population. First described by Gass, they comprise a diverse group of capillary changes in foveal and parafoveal areas and can be divided into three distinct types with different features in fluorescein angiography (FA) and optical coherence tomography (OCT). Treatment options are scarce and mostly confined to unilateral type I JRT. The purpose of this work was to describe functional and morphological outcome of patients treated with intravitreal bevacizumab.

Methods:: Retrospective case series of three male patients with JRT. After informed consent, all patients received intravitreal bevacizumab 1,0mg/0,1ml. One patient had unilateral JRT (type I) and was treated once, while two patients had bilateral JRT (type II) and were treated thrice on a monthly basis. Follow-up was 4 months in all patients and comprised BCVA, ophthalmologic examination, FA and OCT.

Results:: Single intravitreal bevacizumab injection resulted in a marked increase in BCVA from 20/50 to 20/20 during the first 4 weeks after injection in the patient with type I JRT. This was sustained over the next 3 months of follow-up. Leakage on FA and macular oedema on OCT decreased significantly. In contrast, in the patients with type II JRT, leakage on FA decreased likewise, but this was not accompanied by an increase in BCVA despite triple injections. Small cystic changes seen on OCT remained unchanged.

Conclusions:: Patients with type I JRT with pronounced macular oedema on OCT may benefit from intravitreal bevacizumab injections showing functional as well as morphological improvement, while patients with type II JRT with minimal cystic changes on OCT do not show functional improvement.

Keywords: macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×